Biogen Drug Patent Portfolio
Biogen owns 6 orange book drugs protected by 45 US patents with Qalsody having the least patent protection, holding only 3 patents. And Tecfidera with maximum patent protection, holding 15 patents. and owns 1 purple book drug protected by 32 US patents Given below is the list of Biogen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11236121 | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid | 23 Aug, 2037 | Active |
| US11884696 | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid | 23 Aug, 2037 | Active |
| US10844416 | Manganese supplementation for control of glycosylation in mammalian cell culture process | 01 Jun, 2036 | Active |
| US12013403 | Compositions and methods for detection of SMN protein in a subject and treatment of a subject | 04 Mar, 2036 | Active |
| US11268119 | Copper supplementation for control of glycosylation in mammalian cell culture process | 21 Feb, 2036 | Active |
| US10959972 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11007166 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11007167 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11129806 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US11246850 | Methods of treating multiple sclerosis | 16 Nov, 2035 | Active |
| US10436802 | Methods for treating spinal muscular atrophy | 11 Sep, 2035 | Active |
| US11124760 | Methods for overcoming glutamine deprivation during mammalian cell culture | 27 Aug, 2035 | Active |
| US10385341 | Compositions for modulating SOD-1 expression | 01 Apr, 2035 | Active |
| US10669546 | Compositions for modulating SOD-1 expression | 01 Apr, 2035 | Active |
| US10968453 | Compositions for modulating SOD-1 expression | 01 Apr, 2035 | Active |
| US10023831 | Gas delivery devices and associated systems and methods | 17 Mar, 2035 | Active |
| US10391160 | Dimethyl fumarate and vaccination regimens | 13 Mar, 2035 | Active |
| US10555993 | Dimethyl fumarate and vaccination regimens | 13 Mar, 2035 | Active |
| US10994003 | Dimethyl fumarate and vaccination regimens | 13 Mar, 2035 | Active |
| US10676772 | Control of protein glycosylation by culture medium supplementation and cell culture process parameters | 19 Aug, 2034 | Active |
| US9994968 | Electrochemical etching apparatus | 19 Aug, 2034 | Active |
| US10119976 | Method of assessing risk of PML | 27 May, 2034 | Active |
| US10677803 | Method of assessing risk of PML | 27 May, 2034 | Active |
| US11280794 | Method of assessing risk of PML | 27 May, 2034 | Active |
| US10172871 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | 17 Apr, 2034 | Active |
| US10342810 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | 17 Apr, 2034 | Active |
| US9512165 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof | 17 Apr, 2034 | Active |
| US9926559 | Compositions and methods for modulation of SMN2 splicing in a subject | 09 Jan, 2034 | Active |
| US8669281 | Prodrugs of fumarates and their use in treating various diseases | 29 Oct, 2033 | Active |
| US10080733 | Prodrugs of fumarates and their use in treating various diseases | 20 Sep, 2033 | Active |
| US9090558 | Prodrugs of fumarates and their use in treating various diseases | 20 Sep, 2033 | Active |
| US9562252 | Methods of preventing and removing trisulfide bonds | 11 May, 2033 | Active |
| US8993640 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | 24 Apr, 2033 | Active |
| US9701709 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof | 24 Apr, 2033 | Active |
| US10590454 | Methods of preventing and removing trisulfide bonds | 11 May, 2032 | Active |
| US9790533 | Methods of preventing and removing trisulfide bonds | 11 May, 2032 | Active |
| US9316641 | Assay for JC virus antibodies | 09 Jan, 2032 | Active |
| US9109015 | Method of isolating biomacromolecules using low pH and divalent cations | 13 Aug, 2031 | Active |
| US8809049 | Methods for producing mammalian cells | 22 May, 2031 | Active |
| US10308706 | Methods of preventing and removing trisulfide bonds | 05 Feb, 2031 | Active |
| US8318416 | Nutrient monitoring and feedback control for increased bioproduct production | 20 Jan, 2031 | Active |
| US10444234 | Assay for JC virus antibodies | 11 Jan, 2031 | Active |
| US11287423 | Assay for JC virus antibodies | 11 Jan, 2031 | Active |
| US9096879 | Method of supplementing culture media to prevent undesirable amino acid substitutions | 07 Jan, 2031 | Active |
| US8361977 | Compositions and methods for modulation of SMN2 splicing | 23 Dec, 2030 | Active |
| US9212379 | Nutrient monitoring and feedback control for increased bioproduct production | 28 Nov, 2030 | Active |
| US8980853 | Compositions and methods for modulation of SMN2 splicing in a subject | 24 Nov, 2030 | Active |
| US9005926 | Methods of preventing and removing trisulfide bonds | 01 Oct, 2030 | Active |
| US9717750 | Compositions and methods for modulation of SMN2 splicing in a subject | 17 Jun, 2030 | Active |
| US9696307 | Methods for the detection of JC polyoma virus | 05 Feb, 2030 | Active |
| US8124799 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 03 Dec, 2029 | Active |
| US11091430 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 | 20 Apr, 2029 | Active |
| US11919838 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 20 Apr, 2029 | Active |
| US8440854 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 | 20 Apr, 2029 | Active |
| US9670147 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 | 20 Apr, 2029 | Active |
| US8399514 | Treatment for multiple sclerosis | 07 Feb, 2028 | Active |
| US8124350 | Methods and products for evaluating an immune response to a therapeutic protein | 02 Aug, 2027 | Active |
| US7838657 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | 11 Jul, 2027 | Active |
| US9493567 | Methods of treating inflammatory and autoimmune diseases with natalizumab | 05 Mar, 2027 | Active |
| US10233245 | Methods of treating inflammatory and autoimmune diseases with natalizumab | 28 Feb, 2027 | Active |
| US11292845 | Methods of treating inflammatory and autoimmune diseases with natalizumab | 28 Feb, 2027 | Active |
| US8871449 | Methods and products for evaluating an immune response to a therapeutic protein | 12 Apr, 2026 | Active |
| US10705095 | Methods and products for evaluating an immune response to a therapeutic protein | 04 Apr, 2026 | Active |
| US9709575 | Methods and products for evaluating an immune response to a therapeutic protein | 04 Apr, 2026 | Active |
| US10266822 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | 05 Dec, 2025 | Expired |
| US8110560 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences | 05 Dec, 2025 | Expired |
| US7157276 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures | 21 Jun, 2024 | Active |
| US7759117 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures | 21 Jun, 2024 | Active |
| US7101993 | Oligonucleotides containing 2′-O-modified purines | 05 Sep, 2023 | Expired |
| US7320999 | Dimethyl fumarate for the treatment of multiple sclerosis | 18 May, 2020 | Expired |
| US6509376 | Utilization of dialkyfumarates | 29 Oct, 2019 | Expired |
| US6210892 | Alteration of cellular behavior by antisense modulation of mRNA processing | 07 Oct, 2018 | Expired |
| US8759393 | Utilization of dialkylfumarates | 04 Jul, 2018 | Expired |
| US7619001 | Utilization of dialkylfumarates | 01 Apr, 2018 | Expired |
| US7803840 | Utilization of dialkylfumarates | 01 Apr, 2018 | Expired |
| US8524773 | Utilization of dialkylfumarates | 01 Apr, 2018 | Expired |
| US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions | 26 Dec, 2017 | Expired |
Latest Legal Activities on Biogen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Biogen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jun, 2024 | US8361977 |
| Resp. to req. for info. sent under 37 CFR 1.750 | 03 Jun, 2024 | US8669281 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10669546 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10968453 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9512165 |
| Second letter to regulating agency to determine regulatory review period | 22 May, 2024 | US10385341 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9670147 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US11091430 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8993640 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8124799 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US8440854 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US9701709 |
|
Withdrawal of Application for PTE
Critical
| 01 May, 2024 | US10080733 |
|
Withdrawal of Application for PTE
Critical
| 01 May, 2024 | US9090558 |
| Requirement for information sent under 37 CFR 1.750 | 04 Apr, 2024 | US9090558 |
Biogen's Drug Patent Litigations
Biogen's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 01, 2015, against patent number US8399514. The petitioner Coalition for Affordable Drugs V LLC, challenged the validity of this patent, with Biogen MA Inc. as the respondent. Click below to track the latest information on how companies are challenging Biogen's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8399514 | July, 2018 |
Terminated
(03 Feb, 2023)
| Biogen MA Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8399514 | July, 2018 |
Final Written Decision
(03 Feb, 2023)
| Biogen MA Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8399514 | March, 2019 |
Terminated
(11 Sep, 2019)
| Biogen MA Inc. | Sawai USA, Inc. et al. |
| US8399514 | September, 2015 |
Final Written Decision
(21 Mar, 2017)
| Biogen Idec MA Inc | Coalition For Affordable Drugs V LLC et al. |
| US8399514 | September, 2015 |
FWD Entered
(21 Mar, 2017)
| Biogen Idec MA Inc | Coalition For Affordable Drugs V LLC |
| US8759393 | April, 2015 |
Terminated-Denied
(27 Oct, 2015)
| Biogen International GmbH | Coalition For Affordable Drugs V LLC |
| US8759393 | April, 2015 |
Institution Denied
(27 Oct, 2015)
| Biogen International GmbH | Coalition For Affordable Drugs V LLC et al. |
| US8399514 | May, 2015 |
Institution Denied
(02 Sep, 2015)
| Biogen MA Inc. | Coalition for Affordable Drugs V LLC et al. |
| US8399514 | May, 2015 |
Terminated-Denied
(02 Sep, 2015)
| Biogen MA Inc. | Coalition for Affordable Drugs V LLC |
Biogen Drug Patents' Oppositions Filed in EPO
Biogen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 05, 2014, by Zentiva K.S.. This opposition was filed on patent number EP08725256A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13169139A | Apr, 2023 | Dr. Schön, Neymeyr & Partner Patentanwälte mbB | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | BIOGARAN | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Kraus & Weisert Patentanwälte PartGmbB | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Glenmark Pharmaceuticals Europe Ltd | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP13169139A | Apr, 2023 | Adalvo Ltd. | Granted and Under Opposition |
| EP13169139A | Mar, 2023 | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | Granted and Under Opposition |
| EP13169139A | Feb, 2023 | Stada-Arzneimittel Aktiengesellschaft | Granted and Under Opposition |
| EP13169139A | Oct, 2022 | G. L. Pharma GmbH | Granted and Under Opposition |
| EP13169139A | Sep, 2022 | Zentiva k.s. | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | Polpharma S.A. | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | Hexal AG | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | Generics [UK] Limited (trading as Mylan) | Granted and Under Opposition |
| EP13169139A | Jul, 2022 | neuraxpharm Arzneimittel GmbH | Granted and Under Opposition |
| EP17203913A | Jun, 2019 | Taylor Wessing LLP | Granted and Under Opposition |
| EP14767892A | Mar, 2019 | Generics (UK) Ltd | Granted and Under Opposition |
| EP14767892A | Mar, 2019 | Hexal AG | Granted and Under Opposition |
| EP14767892A | Mar, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP08725256A | Feb, 2014 | Forward Pharma A/S | Revoked |
| EP08725256A | Feb, 2014 | Synthon B.V. | Revoked |
| EP08725256A | Feb, 2014 | Actavis Group PTC ehf | Revoked |
| EP08725256A | Feb, 2014 | Gallafent, Antony Xavier | Revoked |
| EP08725256A | Feb, 2014 | Generics [UK] Limited | Revoked |
| EP08725256A | Feb, 2014 | ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. | Revoked |
| EP08725256A | Feb, 2014 | European Opposition Limited | Revoked |
| EP08725256A | Feb, 2014 | G. L. Pharma GmbH | Revoked |
| EP08725256A | Feb, 2014 | Hexal AG | Revoked |
| EP08725256A | Feb, 2014 | Zentiva k.s. | Revoked |
Biogen's Family Patents
Biogen drugs have patent protection in a total of 41 countries. It's US patent count contributes only to 29.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Biogen Drug List
Given below is the complete list of Biogen's drugs and the patents protecting them.
1. Qalsody
Qalsody is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10385341 | Compositions for modulating SOD-1 expression |
01 Apr, 2035
(9 years from now)
| Active |
| US10669546 | Compositions for modulating SOD-1 expression |
01 Apr, 2035
(9 years from now)
| Active |
| US10968453 | Compositions for modulating SOD-1 expression |
01 Apr, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qalsody's drug page
2. Skyclarys
Skyclarys is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8993640 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
24 Apr, 2033
(7 years from now)
| Active |
| US9701709 | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
24 Apr, 2033
(7 years from now)
| Active |
| US8124799 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
03 Dec, 2029
(3 years from now)
| Active |
| US11091430 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
20 Apr, 2029
(3 years from now)
| Active |
| US11919838 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
20 Apr, 2029
(3 years from now)
| Active |
| US8440854 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
20 Apr, 2029
(3 years from now)
| Active |
| US9670147 | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
20 Apr, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Skyclarys's drug page
3. Spinraza
Spinraza is protected by 12 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12013403 | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
04 Mar, 2036
(10 years from now)
| Active |
| US10436802 | Methods for treating spinal muscular atrophy |
11 Sep, 2035
(9 years from now)
| Active |
| US9926559 | Compositions and methods for modulation of SMN2 splicing in a subject |
09 Jan, 2034
(8 years from now)
| Active |
| US8361977 | Compositions and methods for modulation of SMN2 splicing |
23 Dec, 2030
(4 years from now)
| Active |
| US8980853 | Compositions and methods for modulation of SMN2 splicing in a subject |
24 Nov, 2030
(4 years from now)
| Active |
| US9717750 | Compositions and methods for modulation of SMN2 splicing in a subject |
17 Jun, 2030
(4 years from now)
| Active |
| US7838657 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
11 Jul, 2027
(1 year, 6 months from now)
| Active |
| US10266822 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
05 Dec, 2025
(a month ago)
| Expired |
| US8110560 | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
05 Dec, 2025
(a month ago)
| Expired |
| US7101993 | Oligonucleotides containing 2′-O-modified purines |
05 Sep, 2023
(2 years ago)
| Expired |
| US6210892 | Alteration of cellular behavior by antisense modulation of mRNA processing |
07 Oct, 2018
(7 years ago)
| Expired |
| US6166197 | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
26 Dec, 2017
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spinraza's drug page
4. Tecfidera
Tecfidera is protected by 15 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10959972 | Methods of treating multiple sclerosis |
16 Nov, 2035
(9 years from now)
| Active |
| US11007166 | Methods of treating multiple sclerosis |
16 Nov, 2035
(9 years from now)
| Active |
| US11007167 | Methods of treating multiple sclerosis |
16 Nov, 2035
(9 years from now)
| Active |
| US11129806 | Methods of treating multiple sclerosis |
16 Nov, 2035
(9 years from now)
| Active |
| US11246850 | Methods of treating multiple sclerosis |
16 Nov, 2035
(9 years from now)
| Active |
| US10391160 | Dimethyl fumarate and vaccination regimens |
13 Mar, 2035
(9 years from now)
| Active |
| US10555993 | Dimethyl fumarate and vaccination regimens |
13 Mar, 2035
(9 years from now)
| Active |
| US10994003 | Dimethyl fumarate and vaccination regimens |
13 Mar, 2035
(9 years from now)
| Active |
| US8399514 | Treatment for multiple sclerosis |
07 Feb, 2028
(2 years from now)
| Active |
| US7320999 | Dimethyl fumarate for the treatment of multiple sclerosis |
18 May, 2020
(5 years ago)
| Expired |
| US6509376 | Utilization of dialkyfumarates |
29 Oct, 2019
(6 years ago)
| Expired |
| US8759393 | Utilization of dialkylfumarates |
04 Jul, 2018
(7 years ago)
| Expired |
| US7619001 | Utilization of dialkylfumarates |
01 Apr, 2018
(7 years ago)
| Expired |
| US7803840 | Utilization of dialkylfumarates |
01 Apr, 2018
(7 years ago)
| Expired |
| US8524773 | Utilization of dialkylfumarates |
01 Apr, 2018
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tecfidera's drug page
5. Vumerity
Vumerity is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8669281 | Prodrugs of fumarates and their use in treating various diseases |
29 Oct, 2033
(7 years from now)
| Active |
| US10080733 | Prodrugs of fumarates and their use in treating various diseases |
20 Sep, 2033
(7 years from now)
| Active |
| US9090558 | Prodrugs of fumarates and their use in treating various diseases |
20 Sep, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vumerity's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Zurzuvae
Zurzuvae is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11236121 | Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid |
23 Aug, 2037
(11 years from now)
| Active |
| US11884696 | Crystalline 19-nor C3,3-disubstituted C21-n-pyrazolyl steroid |
23 Aug, 2037
(11 years from now)
| Active |
| US10172871 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
17 Apr, 2034
(8 years from now)
| Active |
| US10342810 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
17 Apr, 2034
(8 years from now)
| Active |
| US9512165 | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
17 Apr, 2034
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zurzuvae's drug page
7. Tysabri
Tysabri is protected by 32 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10844416 | Manganese supplementation for control of glycosylation in mammalian cell culture process |
01 Jun, 2036
(10 years from now)
| Active |
| US11268119 | Copper supplementation for control of glycosylation in mammalian cell culture process |
21 Feb, 2036
(10 years from now)
| Active |
| US11124760 | Methods for overcoming glutamine deprivation during mammalian cell culture |
27 Aug, 2035
(9 years from now)
| Active |
| US10023831 | Gas delivery devices and associated systems and methods |
17 Mar, 2035
(9 years from now)
| Active |
| US10676772 | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
19 Aug, 2034
(8 years from now)
| Active |
| US9994968 | Electrochemical etching apparatus |
19 Aug, 2034
(8 years from now)
| Active |
| US10119976 | Method of assessing risk of PML |
27 May, 2034
(8 years from now)
| Active |
| US10677803 | Method of assessing risk of PML |
27 May, 2034
(8 years from now)
| Active |
| US11280794 | Method of assessing risk of PML |
27 May, 2034
(8 years from now)
| Active |
| US9562252 | Methods of preventing and removing trisulfide bonds |
11 May, 2033
(7 years from now)
| Active |
| US10590454 | Methods of preventing and removing trisulfide bonds |
11 May, 2032
(6 years from now)
| Active |
| US9790533 | Methods of preventing and removing trisulfide bonds |
11 May, 2032
(6 years from now)
| Active |
| US9316641 | Assay for JC virus antibodies |
09 Jan, 2032
(6 years from now)
| Active |
| US9109015 | Method of isolating biomacromolecules using low pH and divalent cations |
13 Aug, 2031
(5 years from now)
| Active |
| US8809049 | Methods for producing mammalian cells |
22 May, 2031
(5 years from now)
| Active |
| US10308706 | Methods of preventing and removing trisulfide bonds |
05 Feb, 2031
(5 years from now)
| Active |
| US8318416 | Nutrient monitoring and feedback control for increased bioproduct production |
20 Jan, 2031
(5 years from now)
| Active |
| US10444234 | Assay for JC virus antibodies |
11 Jan, 2031
(5 years from now)
| Active |
| US11287423 | Assay for JC virus antibodies |
11 Jan, 2031
(5 years from now)
| Active |
| US9096879 | Method of supplementing culture media to prevent undesirable amino acid substitutions |
07 Jan, 2031
(4 years from now)
| Active |
| US9212379 | Nutrient monitoring and feedback control for increased bioproduct production |
28 Nov, 2030
(4 years from now)
| Active |
| US9005926 | Methods of preventing and removing trisulfide bonds |
01 Oct, 2030
(4 years from now)
| Active |
| US9696307 | Methods for the detection of JC polyoma virus |
05 Feb, 2030
(4 years from now)
| Active |
| US8124350 | Methods and products for evaluating an immune response to a therapeutic protein |
02 Aug, 2027
(1 year, 6 months from now)
| Active |
| US9493567 | Methods of treating inflammatory and autoimmune diseases with natalizumab |
05 Mar, 2027
(1 year, 1 month from now)
| Active |
| US10233245 | Methods of treating inflammatory and autoimmune diseases with natalizumab |
28 Feb, 2027
(1 year, 1 month from now)
| Active |
| US11292845 | Methods of treating inflammatory and autoimmune diseases with natalizumab |
28 Feb, 2027
(1 year, 1 month from now)
| Active |
| US8871449 | Methods and products for evaluating an immune response to a therapeutic protein |
12 Apr, 2026
(3 months from now)
| Active |
| US10705095 | Methods and products for evaluating an immune response to a therapeutic protein |
04 Apr, 2026
(2 months from now)
| Active |
| US9709575 | Methods and products for evaluating an immune response to a therapeutic protein |
04 Apr, 2026
(2 months from now)
| Active |
| US7157276 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
21 Jun, 2024
(1 year, 6 months ago)
| Expired |
| US7759117 | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
21 Jun, 2024
(1 year, 6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tysabri's drug page